Article in American journal of respiratory and critical care medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
David ThickettInstitute of Inflammation and Aging, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0002-5456-6080
R Gisli JenkinsNational Heart and Lung Institute, Imperial Biomedical Research Centre, and National Institute for Health and Care Research Margaret Turner Warwick Centre for Fibrosing Lung Disease, Imperial College London, London, United Kingdom.ORCID 0000-0002-7929-2119
Andrew M WilsonNorwich Medical School, University of East Anglia, Norwich, United Kingdom; and.ORCID 0000-0002-5514-4867
Imre NothDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia.ORCID 0000-0001-9846-5030
Funding
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUH3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2021 to 2025
$11.6M
Multidisciplinary Approach Training in Respiratory ResearchT32HL134629 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Robert J Kaner, Heather Winona Stout Delgado · 2018 to 2026
$5.2M
The role of quantitative CT and radiomic biomarkers for precision medicine in pulmonary fibrosisR01HL171918 · NHLBI · UNIVERSITY OF VIRGINIA · PI Imre Noth · 2024 to 2026
$2.2M
Gut Microbiota and Host Regulatory Cross-Talk in Pulmonary FibrosisR01HL162659 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI O'DWYER, DAVID NOEL · 2022 to 2025
$1.9M
Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary Fibrosis - CleanUP-IPFU01HL128964 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ANSTROM, KEVIN J, MARTINEZ, FERNANDO J · 2015 to 2018
$1.6M
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUG3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2019 to 2019
$977k
Role of polyunsaturated fatty acids in pulmonary fibrosisK23HL150301 · NHLBI · UNIVERSITY OF VIRGINIA · PI KIM, JOHN S · 2021 to 2025
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.